Wyeth (WYE) Inactive 10-Q2008 Q2 Quarterly report

Filed: 4 Aug 08, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: adequacy, advantage, ALAVERT, Anchen, andBENEFIX, andBENEFIXand, andDeBoard, andPREMPRO, Anthony, anytime, APB, Apotex, apparent, aqui, Attorney, AU, aware, Biovail, bluetongue, borrowing, byZULVAC, calendar, CALTRATEand, contesting, Conversion, cooperate, coordinated, coverage, coversLYBRELand, Cty, daily, deliver, Direct, discretion, Dist, divestedSYNVISC, division, driven, effort, employment, ESI, extension, external, facilitate, false, feedback, Feerick, forEFFEXORnet, forPREMARIN, forPRISTIQa, forVIVIANTfor, FSP, Gamble, grand, heat, Hierarchy, improper, inBailey, includingPREMARINand, indirect, intangible, John, Jr, Jud, Lake, learned, Lederle, life, Livingston, lump, manner, Mark, marketplace, MDL, Middlesex, milestone, month, nonconvertible, nongovernmental, ofBENEFIX, ofCHAPSTICK, ofEFFEXORmay, ofPREMARINor, ofUnited, ourEFFEXORfamily, ourself, outlined, PLA, PREMPRO, presumption, priority, Procter, reacquisition, Robert, rolling, Ruffolo, Salt, Schering, secondary, shipping, Sokol, SRL, subcutaneousRELISTOR, sum, tam, testified, ThermaCare, timeline, toPROTONIXand, tort, TYGACILfor, UT, Utah, Va, Vice, wrap, XRfor

Removed: accounted, andALTACE, andENBREL, andPREVNAR, antidilutive, apply, asENBREL, begin, comparability, computation, coronary, covering, creation, decline, dermatology, dosing, earned, expiring, includingPREMPRO, infringe, inOther, inPROTONIX, inRAPAMUNE, introduction, Johnson, King, largely, making, ofALTACE, offering, orPREMARIN, owner, placebo, prospectively, region, rheumatology, Rico, stent, subsequently, theCYPHER, withstand

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

WYE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Wyeth (the Company) on Form 10-Q for the fiscal quarter ended June 30, 2008, as filed with the Securities and Exchange Commission on August 4, 2008 (the Report), I, Bernard Poussot, Chairman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 4, 2008



By:		/s/ Bernard Poussot
		Bernard Poussot Chairman, President and Chief Executive Officer